A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2004
12/16/2004	US20040253597 Sodium dependent dicarboxylate transport protein for use in identifying modulators for prevention/treatment of hepatic, prostate, splenic, renal diseases, metabolic, circulatory, cancer and aging disorders
12/16/2004	US20040253595 P53-dependent apoptosis-inducing protein and method of screening for apoptosis regulator
12/16/2004	US20040253588 Cytochrome p450 monooxygenase for use in identifying modulators for treatment, diagnosis and prevention of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, gastrointestinal and liver disorders
12/16/2004	US20040253329 Ligand for peroxisome proliferator-activated receptor
12/16/2004	US20040253328 Anti-atypical pneumonia decoction
12/16/2004	US20040253294 A crosslinked, acidic, high molecular weight gelatin hydrogel obtained from alkali hydrolyzed collagen, impregnated with hepatocyte growth factor, and having an isoelectric point of 5 and a zeta potential between -15 and -20 mV; angiogenesis promoters; arterial diseases
12/16/2004	US20040253276 Oil-in-water emulsion of a 1-carboxylate-6-arylsulfamoyl cyclohexene and synthetic and naturally occurring phospholipids; nitric oxide or cytokine prodution inhibitors; cardiovascular disorders, autoimmune dieseases, septic shock; improved stability during autoclave sterilization
12/16/2004	US20040253270 Nucleic acid encoding infectious, nonpathogenic porcine circovirus type-1(PCV1), which contains immunogenic open reading frame gene of pathogenic PCV2 in place of an ORF gene of PCV1 nucleic acid molecule; means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome
12/16/2004	US20040253247 Conjugate comprising a peptide having an engineered amino acid sequence capable of binding a plasma protein, said peptide conjugated to the therapeutic or diagnostic substance, wherein elimination half time of conjugate exceeds that of unconjugated therapeutic or diagnostic substance; peptide ligands
12/16/2004	US20040253233 genetic engineered chimeric and humanized antibodies obtained from murine monoclonal antibody P3 (MAb P3) and its antiidiotypic antibodies, used as antitumor agents
12/16/2004	US20040253231 monoclonal or polyclonal antibodies having specific reactivity with adenosine triphosphate binding domains, caspase recruitment domains and triosephosphate isomerase domain peptides, used for modulation of apoptosis
12/16/2004	US20040253226 administering to the animals angiogenesis inhibitors comprising kallikreins such as prostate specific antigens (PSA), hydrolase enzymes homologs or fragments; prophylaxis of cancer, arthritis and vision defects
12/16/2004	US20040253221 Novel pla1
12/16/2004	US20040253206 etoposide; hydrophobic drug attached to amphiphilic ethylene glycol oligomer or polymer via hydrolyzable bond; improves ability to penetrate blood-brain barrier; bond hydrolyzes in vivo, freeing the fully bioactive drug; improves solubility of the drug in the bloodstream; drug delivery to CNS
12/16/2004	US20040253205 c-Kit kinase inhibitor
12/16/2004	CA2528497A1 Tricyclic compound
12/16/2004	CA2528156A1 Staurosporine derivatives for hypereosinophilic syndrome
12/16/2004	CA2526789A1 Cells used as carriers for bacteria
12/15/2004	EP1486508A1 Use of the AL-1 neurotrophic factor, a ligand for an EPH-related tyrosine kinase receptor, for the preparation of a medicament for modulating angiogenesis associated disease or condition
12/15/2004	EP1486507A1 Transmembrane nfat inhibitory peptide
12/15/2004	EP1486505A1 Angiotensin derivatives
12/15/2004	EP1486503A1 Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them
12/15/2004	EP1486502A1 Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them
12/15/2004	EP1486501A1 Aminomethyl-substituted thiazolobenzimidazole derivative
12/15/2004	EP1486497A1 Novel pyridone derivative
12/15/2004	EP1486496A1 Substituted 2-(2,6-Dioxopiperidin-3-YP)-Phthalimides and 1-Oxoisoindolines and method fo reducing TNF alpha levels
12/15/2004	EP1486495A1 Lipoic acid derivatives and their use in treatment of disease
12/15/2004	EP1486494A1 N-substituted benzothiophenesulfonamide derivative
12/15/2004	EP1486491A1 Carboxyoic acid compounds and drugs containing the compounds as the active ingredient
12/15/2004	EP1486490A1 Azole compounds
12/15/2004	EP1486486A2 Substituted B-thiocarboxylic acids
12/15/2004	EP1486214A1 Botulinum toxins for treating muscle spasm
12/15/2004	EP1486213A1 The use of the total coumarins of cnidium monnieri in preparation of the medicament for treating psoriasis
12/15/2004	EP1486210A1 Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis
12/15/2004	EP1486208A1 Novel preventive for infections
12/15/2004	EP1485482A1 Inhibition of the beta3 subunit of l-type ca 2+ channels
12/15/2004	EP1485477A2 Novel type-1 cytokine receptor glm-r
12/15/2004	EP1485476A2 Dimeric tf antagonist
12/15/2004	EP1485475A1 Hybrid and single chain meganucleases and use thereof
12/15/2004	EP1485472A2 Crystal structure of an aurora kinase catalytic domain, and uses thereof
12/15/2004	EP1485401A1 Trpm-2 antisense therapy using an oligonucleotide having 2'-o-(-2-methoxyl)ethyl modifications
12/15/2004	EP1485391A2 Phosphate transport inhibitors
12/15/2004	EP1485390A1 Bicyclic pyridine and pyrimidine p38 kinase inhibitors
12/15/2004	EP1485388A2 Topiramate salts and compositions comprising and methods of making and using the same
12/15/2004	EP1485384A1 Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
12/15/2004	EP1485379A1 Beta 3-adrenergic receptor agonists
12/15/2004	EP1485378A1 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
12/15/2004	EP1485377A1 Pyranones useful as atm inhibitors
12/15/2004	EP1485371A2 Indole amide derivatives and their use as glycogen phosphorylase inhibitors
12/15/2004	EP1485370A1 Amino-derivatives as novel inhibitors of histone deacetylase
12/15/2004	EP1485368A1 Substituted chroman derivatives having cytochrome p450rai inhibitory activity
12/15/2004	EP1485365A1 Sulfonyl-derivatives as novel inhibitors of histone deacetylase
12/15/2004	EP1485364A1 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
12/15/2004	EP1485363A1 Cyclic amides
12/15/2004	EP1485362A1 Crystalline parecoxib sodium
12/15/2004	EP1485360A2 Sodium channel blockers
12/15/2004	EP1485358A1 Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
12/15/2004	EP1485354A1 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
12/15/2004	EP1485353A1 New inhibitors of histone deacetylase
12/15/2004	EP1485347A2 Hif hydroxylase inhibitors
12/15/2004	EP1485345A2 Urokinase inhibitors, production and use thereof
12/15/2004	EP1485168A1 Combination of a cdk inhibitor and 5-fu for the treatment of cancer
12/15/2004	EP1485160A1 Intraductal management of breast lesions involving therapeutic or diagnostic agents
12/15/2004	EP1485145A1 Multiple compartment bag assembly for dialysis fluid
12/15/2004	EP1485140A1 Polymer composite loaded with cells
12/15/2004	EP1485131A1 Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
12/15/2004	EP1485126A2 Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
12/15/2004	EP1485118A2 Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy
12/15/2004	EP1485114A2 Isolation, purification and structural identification of a bioactive component of a water soluble extract of a botanical species for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
12/15/2004	EP1485109A1 Vascular therapeutics
12/15/2004	EP1485104A1 Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
12/15/2004	EP1485099A1 Inhibitors of histone deacetylase
12/15/2004	EP1485098A1 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine in nanoparticulate form
12/15/2004	EP1485095A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
12/15/2004	EP1485094A1 FORM OF PRESENTATION FOR 3- (2-{ 4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO -METHYL}-1-METHYL-1iH /i -BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO PROPIONIC ACID ETHYL ESTER TO BE ADMINISTERED ORALLY
12/15/2004	EP1485092A1 Use of rapamycin for inhibiting of cell death
12/15/2004	EP1485090A2 Combinations comprising epothilone derivatives and alkylating agents
12/15/2004	EP1485088A1 Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
12/15/2004	EP1485087A1 (+)-2- 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
12/15/2004	EP1485086A1 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane as nmda, 5ht3, and neuronal nicotinic receptor antagonists
12/15/2004	EP1485085A1 Phosphate prodrugs of fluorooxindoles
12/15/2004	EP1485079A2 Small molecule entry inhibitors
12/15/2004	EP1485074A2 Compositions for treating digestive functional pathologies
12/15/2004	EP1485073A2 Method for administration of growth hormone via pulmonary delivery
12/15/2004	EP1485068A2 hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
12/15/2004	EP1485067A2 Materials containing multiple layers of vesicles
12/15/2004	EP1436285A4 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
12/15/2004	EP1414470A4 Micronutrient phosphates as dietary and health supplements
12/15/2004	EP1399155A4 Small molecules useful in the treatment of inflammatory disease
12/15/2004	EP1387840B1 3,5-diamino-1,2,4-triazoles as kinase inhibitors
12/15/2004	EP1383515B1 Activation of natural killer cells by adenosine a3 receptor agonists
12/15/2004	EP1373216B1 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
12/15/2004	EP1322301B1 Combination particles for the treatment of asthma
12/15/2004	EP1322300B1 Inhalation particles incorporating a combination of two or more active ingredients
12/15/2004	EP1320533A4 Prodrugs of a 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotic
12/15/2004	EP1307447B1 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
12/15/2004	EP1283056B1 Medicinal compositions promoting bowel movement
12/15/2004	EP1263711B1 Novel use of phenylheteroalkylamine derivatives
12/15/2004	EP1249245B1 Remedies and/or preventives for nervous system disorders
12/15/2004	EP1226160B1 Novel antiarrhythmic peptides

1 ... 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 ... 1564